Global Decentralised Clinical Trials Market Size Study, by Study Design, by Indication, by Component, by End-users and Regional Forecasts 2022-2032

Description

Global Decentralised Clinical Trials Market is valued at approximately USD 9.30 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 15.40% over the forecast period 2024-2032. Decentralised Clinical Trials (DCTs) has revolutionized the landscape of clinical research, offering a paradigm shift in how trials are conducted. This innovative approach leverages digital health technologies, enabling remote monitoring and data collection, thus enhancing participant convenience and broadening patient diversity. The driving force behind this market surge includes the imperative to accelerate drug development timelines, mitigate costs, and increase the accessibility of diverse treatments to among large number of patients.

The globalization of clinical trials underscores a transformative era in the healthcare sector, driven by an extensive reach across various geographies. Pharmaceutical and biotech companies are heavily investing in these trials to garner comprehensive data from diverse demographic groups. This inclusivity in clinical trials fosters a deeper understanding of treatment efficacies across different genetic and socio-economic backgrounds, unveiling critical insights into potential side effects and drug responses. Moreover, regulatory harmonization has streamlined approval processes across multiple countries, reducing redundant efforts and expediting the introduction of breakthrough therapies to the market. However, concerns regarding data privacy and security and regulatory compliance are going to impede the overall demand for the market during the forecast period 2024-2032.

The key regions considered for the Global Decentralised Clinical Trials Market study include Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America was the dominating among regional market in terms of revenue owing to factors such as advanced healthcare infrastructure and the presence of major pharmaceutical companies. Regulatory bodies such as the FDA have been increasingly supportive of DCTs, providing guidelines and frameworks that facilitate the adoption of these trials. This regulatory environment encourages pharmaceutical companies to explore decentralized models. Furthermore, the market in Asia Pacific is anticipated to develop at the fastest rate over the forecast period 2024-2032.

Major market players included in this report are:

ICON plc
Medpace Holdings, Inc.
Parexel International Corporation
PPD, Inc.
Covance Inc.
LabCorp Drug Development
PRA Health Sciences
Syneos Health
IQVIA Holdings Inc.
Charles River Laboratories International, Inc

The detailed segments and sub-segment of the market are explained below:

By Study Design

Interventional
Observational
Expanded Access

By Indication

Oncology
Cardiovascular
Immunology
Respiratory
Others

By Component

Mobile Healthcare
Telemedicine
Wearable Devices
Web-based Technology
Others

By End-users

Pharmaceutical and Biopharmaceutical Companies
CROs
Others

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
Saudi Arabia
South Africa
RoMEA

Years considered for the study are as follows:

Historical year - 2022
Base year - 2023
Forecast period - 2024 to 2032

Key Takeaways:

Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

Chapter 1. Global Decentralised Clinical Trials Market Executive Summary

1.1. Global Decentralised Clinical Trials Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
- 1.3.1. By Study Design
- 1.3.2. By Indication
- 1.3.3. By Component
- 1.3.4. By End-users
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion

Chapter 2. Global Decentralised Clinical Trials Market Definition and Research Assumptions

2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
  - 2.3.3.1. Availability
  - 2.3.3.2. Infrastructure
  - 2.3.3.3. Regulatory Environment
  - 2.3.3.4. Market Competition
  - 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
  - 2.3.4.1. Regulatory frameworks
  - 2.3.4.2. Technological Advancements
  - 2.3.4.3. Environmental Considerations
  - 2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates

Chapter 3. Global Decentralised Clinical Trials Market Dynamics

3.1. Market Drivers
- 3.1.1. Accelerated Drug Development
- 3.1.2. Cost Reduction
- 3.1.3. Access to Diverse Populations
3.2. Market Challenges
- 3.2.1. Data Privacy and Security Concerns
- 3.2.2. Regulatory Compliance
3.3. Market Opportunities
- 3.3.1. Technological Advancements
- 3.3.2. Expansion in Emerging Markets
- 3.3.3. Increased Collaboration and Data Exchange

Chapter 4. Global Decentralised Clinical Trials Market Industry Analysis

4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis
4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion

Chapter 5. Global Decentralised Clinical Trials Market Size & Forecasts by Study Design 2022-2032

5.1. Segment Dashboard
5.2. Global Decentralised Clinical Trials Market: Study Design Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 5.2.1. Interventional
- 5.2.2. Observational
- 5.2.3. Expanded Access

Chapter 6. Global Decentralised Clinical Trials Market Size & Forecasts by Indication 2022-2032

6.1. Segment Dashboard
6.2. Global Decentralised Clinical Trials Market: Indication Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 6.2.1. Oncology
- 6.2.2. Cardiovascular
- 6.2.3. Immunology
- 6.2.4. Respiratory
- 6.2.5. Others

Chapter 7. Global Decentralised Clinical Trials Market Size & Forecasts by Component 2022-2032

7.1. Segment Dashboard
7.2. Global Decentralised Clinical Trials Market: Component Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 7.2.1. Mobile Healthcare
- 7.2.2. Telemedicine
- 7.2.3. Wearable Devices
- 7.2.4. Web-based Technology
- 7.2.5. Others

Chapter 8. Global Decentralised Clinical Trials Market Size & Forecasts by End-users 2022-2032

8.1. Segment Dashboard
8.2. Global Decentralised Clinical Trials Market: End-users Revenue Trend Analysis, 2022 & 2032 (USD Billion)
- 8.2.1. Pharmaceutical and Biopharmaceutical Companies
- 8.2.2. CROs
- 8.2.3. Others

Chapter 9. Global Decentralised Clinical Trials Market Size & Forecasts by Region 2022-2032

9.1. North America Decentralised Clinical Trials Market
- 9.1.1. U.S. Decentralised Clinical Trials Market
  - 9.1.1.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.1.1.2. Indication breakdown size & forecasts, 2022-2032
  - 9.1.1.3. Component breakdown size & forecasts, 2022-2032
  - 9.1.1.4. End-users breakdown size & forecasts, 2022-2032
- 9.1.2. Canada Decentralised Clinical Trials Market
  - 9.1.2.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.1.2.2. Indication breakdown size & forecasts, 2022-2032
  - 9.1.2.3. Component breakdown size & forecasts, 2022-2032
  - 9.1.2.4. End-users breakdown size & forecasts, 2022-2032
9.2. Europe Decentralised Clinical Trials Market
- 9.2.1. U.K. Decentralised Clinical Trials Market
  - 9.2.1.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.1.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.1.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.1.4. End-users breakdown size & forecasts, 2022-2032
- 9.2.2. Germany Decentralised Clinical Trials Market
  - 9.2.2.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.2.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.2.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.2.4. End-users breakdown size & forecasts, 2022-2032
- 9.2.3. France Decentralised Clinical Trials Market
  - 9.2.3.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.3.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.3.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.3.4. End-users breakdown size & forecasts, 2022-2032
- 9.2.4. Spain Decentralised Clinical Trials Market
  - 9.2.4.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.4.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.4.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.4.4. End-users breakdown size & forecasts, 2022-2032
- 9.2.5. Italy Decentralised Clinical Trials Market
  - 9.2.5.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.5.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.5.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.5.4. End-users breakdown size & forecasts, 2022-2032
- 9.2.6. Rest of Europe Decentralised Clinical Trials Market
  - 9.2.6.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.2.6.2. Indication breakdown size & forecasts, 2022-2032
  - 9.2.6.3. Component breakdown size & forecasts, 2022-2032
  - 9.2.6.4. End-users breakdown size & forecasts, 2022-2032
9.3. Asia-Pacific Decentralised Clinical Trials Market
- 9.3.1. China Decentralised Clinical Trials Market
  - 9.3.1.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.1.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.1.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.1.4. End-users breakdown size & forecasts, 2022-2032
- 9.3.2. India Decentralised Clinical Trials Market
  - 9.3.2.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.2.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.2.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.2.4. End-users breakdown size & forecasts, 2022-2032
- 9.3.3. Japan Decentralised Clinical Trials Market
  - 9.3.3.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.3.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.3.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.3.4. End-users breakdown size & forecasts, 2022-2032
- 9.3.4. Australia Decentralised Clinical Trials Market
  - 9.3.4.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.4.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.4.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.4.4. End-users breakdown size & forecasts, 2022-2032
- 9.3.5. South Korea Decentralised Clinical Trials Market
  - 9.3.5.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.5.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.5.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.5.4. End-users breakdown size & forecasts, 2022-2032
- 9.3.6. Rest of Asia Pacific Decentralised Clinical Trials Market
  - 9.3.6.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.3.6.2. Indication breakdown size & forecasts, 2022-2032
  - 9.3.6.3. Component breakdown size & forecasts, 2022-2032
  - 9.3.6.4. End-users breakdown size & forecasts, 2022-2032
9.4. Latin America Decentralised Clinical Trials Market
- 9.4.1. Brazil Decentralised Clinical Trials Market
  - 9.4.1.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.4.1.2. Indication breakdown size & forecasts, 2022-2032
  - 9.4.1.3. Component breakdown size & forecasts, 2022-2032
  - 9.4.1.4. End-users breakdown size & forecasts, 2022-2032
- 9.4.2. Mexico Decentralised Clinical Trials Market
  - 9.4.2.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.4.2.2. Indication breakdown size & forecasts, 2022-2032
  - 9.4.2.3. Component breakdown size & forecasts, 2022-2032
  - 9.4.2.4. End-users breakdown size & forecasts, 2022-2032
- 9.4.3. Rest of Latin America Decentralised Clinical Trials Market
  - 9.4.3.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.4.3.2. Indication breakdown size & forecasts, 2022-2032
  - 9.4.3.3. Component breakdown size & forecasts, 2022-2032
  - 9.4.3.4. End-users breakdown size & forecasts, 2022-2032
9.5. Middle East & Africa Decentralised Clinical Trials Market
- 9.5.1. Saudi Arabia Decentralised Clinical Trials Market
  - 9.5.1.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.5.1.2. Indication breakdown size & forecasts, 2022-2032
  - 9.5.1.3. Component breakdown size & forecasts, 2022-2032
  - 9.5.1.4. End-users breakdown size & forecasts, 2022-2032
- 9.5.2. South Africa Decentralised Clinical Trials Market
  - 9.5.2.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.5.2.2. Indication breakdown size & forecasts, 2022-2032
  - 9.5.2.3. Component breakdown size & forecasts, 2022-2032
  - 9.5.2.4. End-users breakdown size & forecasts, 2022-2032
- 9.5.3. Rest of Middle East & Africa Decentralised Clinical Trials Market
  - 9.5.3.1. Study Design breakdown size & forecasts, 2022-2032
  - 9.5.3.2. Indication breakdown size & forecasts, 2022-2032
  - 9.5.3.3. Component breakdown size & forecasts, 2022-2032
  - 9.5.3.4. End-users breakdown size & forecasts, 2022-2032

Chapter 10. Competitive Intelligence

10.1. Key Company SWOT Analysis
10.2. Top Market Strategies
10.3. Company Profiles
- 10.3.1. ICON plc
  - 10.3.1.1. Key Information
  - 10.3.1.2. Overview
  - 10.3.1.3. Financial (Subject to Data Availability)
  - 10.3.1.4. Product Summary
  - 10.3.1.5. Market Strategies
- 10.3.2. Medpace Holdings, Inc.
- 10.3.3. Parexel International Corporation
- 10.3.4. PPD, Inc.
- 10.3.5. Covance Inc.
- 10.3.6. LabCorp Drug Development
- 10.3.7. PRA Health Sciences
- 10.3.8. Syneos Health
- 10.3.9. IQVIA Holdings Inc.
- 10.3.10. Charles River Laboratories International, Inc.

Chapter 11. Research Process

11.1. Research Process
- 11.1.1. Data Mining
- 11.1.2. Analysis
- 11.1.3. Market Estimation
- 11.1.4. Validation
- 11.1.5. Publishing
11.2. Research Attributes